Interaction Checker

Interacciones de Pazopanib

Pazopanib (Votrient) tiene 257 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 148; moderadas: 107; leves: 2; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (148)

  • Abrocitinibinhibidor de JAKGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • AlfuzosinaalfabloqueanteGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • AmiodaronaantiarrítmicoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Amitriptilinaantidepresivo tricíclicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Anagrelidafármaco que prolonga el intervalo QTGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Antiácidos (Tums, Maalox, Mylanta)Productos sin recetaGrave

    If concomitant administration with a gastric acid-reducing agent cannot be avoided, consider short-acting antacids in place of PPIs and H2-receptor antagonists. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Grave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • AsenapinaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • AtazanavirantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Azitromicinaantibiótico macrólidoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Bicarbonato de sodioantiácidoGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Grave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • CiclosporinainmunosupresorGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Grave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • CitalopramISRSGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • ClobazambenzodiazepinaGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • CloroquinaantipalúdicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • ClorpromazinaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • ClozapinaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • DarunavirantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Deutetrabenazinainhibidor de VMAT2Grave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Dexlansoprazolinhibidor de la bomba de protonesGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Dextrometorfano y quinidinafármaco serotoninérgicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • DisopiramidaantiarrítmicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • DofetilidaantiarrítmicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Droperidolantagonista de la dopaminaGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • EfavirenzantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • EscitalopramISRSGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Esomeprazolinhibidor de la bomba de protonesGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • EtravirinaantirretroviralGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • EverolimusinmunosupresorGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Famotidinaantagonista H2Grave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • FingolimodinmunosupresorGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • FlecainidaantiarrítmicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Flibanserinadepresor del SNCGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • FluoxetinaISRSGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • FosamprenavirantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Grave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Granisetrónfármaco que prolonga el intervalo QTGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • HaloperidolantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Hidroxicloroquinafármaco que prolonga el intervalo QTGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • HidroxizinaantihistamínicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Ibuprofeno y famotidinaAINEGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • IbutilidaantiarrítmicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • IloperidonaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Grave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • IsoniazidaantibióticoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Grave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Lansoprazolinhibidor de la bomba de protonesGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Lapatinibinhibidor de la glicoproteína PGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Ledipasvir y sofosbuvirantiviralGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • LenacapavirantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • LevofloxacinofluoroquinolonaGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Loperamidafármaco que prolonga el intervalo QTGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Grave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • MetadonaopioideGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Grave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Grave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • MoxifloxacinofluoroquinolonaGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Naproxeno y esomeprazolAINEGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • NefazodonaantidepresivoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • NevirapinaantirretroviralGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Nilotinibfármaco que prolonga el intervalo QTGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Nizatidinaantagonista H2Grave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • OfloxacinofluoroquinolonaGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Olanzapina y fluoxetinaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Omeprazolinhibidor de la bomba de protonesGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Omeprazol y bicarbonato de sodioinhibidor de la bomba de protonesGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Ondansetrónfármaco que prolonga el intervalo QTGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Grave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • PaliperidonaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Pantoprazolinhibidor de la bomba de protonesGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Pentamidinafármaco que prolonga el intervalo QTGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • PerampanelanticonvulsivoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • PimavanserinaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • PimozidaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Pitolisantfármaco que prolonga el intervalo QTGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • PrimidonaanticonvulsivoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • ProcainamidaantiarrítmicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • PrometazinaantihistamínicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Prometazina y codeínaopioideGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Prometazina y dextrometorfanoantihistamínicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • PropafenonaantiarrítmicoGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • QuetiapinaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • QuinidinaantiarrítmicoGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • QuininaantipalúdicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Rabeprazolinhibidor de la bomba de protonesGrave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Ranitidinaantagonista H2Grave

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • RifabutinaantibióticoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • RisperidonaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • RitonavirantirretroviralGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Sofosbuvir y velpatasvirantiviralGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • SolifenacinaanticolinérgicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • SotalolbetabloqueanteGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Grave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • TacrolimusinmunosupresorGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Tamoxifenomodulador selectivo de los receptores de estrógenosGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Tetrabenazinainhibidor de VMAT2Grave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • TioridazinaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • TolterodinaanticolinérgicoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoGrave

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Toremifenomodulador selectivo de los receptores de estrógenosGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • TramadolopioideGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Tramadol y paracetamolopioideGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • TrazodonaantidepresivoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Trióxido de arsénicofármaco que prolonga el intervalo QTGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Valbenazinainhibidor de VMAT2Grave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Vardenafiloinhibidor de la PDE5Grave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • VenlafaxinaIRSNGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoGrave

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • ZiprasidonaantipsicóticoGrave

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etiqueta de Pazopanib, Interacciones medicamentosas)

  • ZonisamidaanticonvulsivoGrave

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etiqueta de Pazopanib, Interacciones medicamentosas)

Interacciones moderadas (107)

  • AcebutololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Ácido etacrínicodiurético de asaModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • AdenosinaantiarrítmicoModerada

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • AliskirenoantihipertensivoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Amiloridadiurético ahorrador de potasioModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Amlodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Amlodipino y olmesartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Amlodipino y valsartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • AtenololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Atenolol y clortalidonabetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • AtorvastatinaestatinaModerada

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Azilsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Benazeprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Benazepril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • BetaxololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • BisoprololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Candesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Captoprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • CarvedilolbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Clonidinaagonista alfa-adrenérgicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Clorotiazidadiurético tiazídicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Clortalidonadiurético tiazídicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Digoxinaglucósido digitálicoModerada

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • Dinitrato de isosorbida e hidralazinanitratoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • DoxazosinaalfabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Enalaprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Enalapril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Enalaprilatoinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Eplerenonaantagonista de la aldosteronaModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • EsmololbetabloqueanteModerada

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • Espironolactonaantagonista de la aldosteronaModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Ezetimiba y simvastatinaestatinaModerada

    Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • Felodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • FenoxibenzaminaalfabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • FluvastatinaestatinaModerada

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Fosinoprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Furosemidadiurético de asaModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Guanfacinaagonista alfa-adrenérgicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • HidralazinavasodilatadorModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Hidroclorotiazidadiurético tiazídicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Indapamidadiurético tiazídicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Irbesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • LabetalolbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Levotiroxinahormona tiroideaModerada

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Levotiroxina y liotironinahormona tiroideaModerada

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Lidocaínaanestésico localModerada

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • Lidocaína y prilocaínaanestésico localModerada

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • Liotironinahormona tiroideaModerada

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Lisinoprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Lofexidinaagonista alfa-adrenérgicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • LomitapidaModerada

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (etiqueta de Lomitapida, Interacciones medicamentosas)

  • Losartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • LovastatinaestatinaModerada

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etiqueta de Pazopanib, Advertencias y precauciones)

  • MecamilaminaantihipertensivoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • MetildopaantihipertensivoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Metimazolfármaco antitiroideoModerada

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Metolazonadiurético tiazídicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • MetoprololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • MexiletinaantiarrítmicoModerada

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • MinoxidilvasodilatadorModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Moexiprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • NadololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • NebivololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Nicardipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • NitroprusiatovasodilatadorModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Olmesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • PemetrexedantimetabolitoModerada

    Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Perindoprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • PindololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • PitavastatinaestatinaModerada

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etiqueta de Pazopanib, Advertencias y precauciones)

  • PravastatinaestatinaModerada

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etiqueta de Pazopanib, Advertencias y precauciones)

  • PrazosinaalfabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Propiltiouracilofármaco antitiroideoModerada

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • PropranololbetabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Quinaprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Quinapril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Ramiprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • RosuvastatinaestatinaModerada

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Sacubitrilo y valsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • SimvastatinaestatinaModerada

    Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • Telmisartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Telmisartán y amlodipinoantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • TerazosinaalfabloqueanteModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Teriparatidahormona tiroideaModerada

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Tizanidinarelajante muscularModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Torasemidadiurético de asaModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Trandolaprilinhibidor de la ECAModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Triamterenodiurético ahorrador de potasioModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Valsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

Menciones leves (2)

  • BevacizumabLeve

    Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (etiqueta de Pazopanib, Advertencias y precauciones)

  • TopotecánLeve

    Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (etiqueta de Pazopanib, Advertencias y precauciones)

Compruebe Pazopanib frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.